Collaborative and Clinical Research

Members of our group are active partners in the design and analysis of clinical studies with time-to-event outcomes, both trials and non-interventional studies. Our activities are mainly concentrated in oncology and hematology, but we also work in other medical fields. Our aim is to have mutual benefit of clinical and methodological research.

We collaborate with various departments from LUMC and external groups.

  • Within LUMC we collaborate, among others, with the departments of Surgery, Oncology, Hematology, and Orthopedics. Some large trials in which we are involved are the Dutch Gastric Cancer Trial, the TME trial, the TEAM trial and PORTEC trial.
  • Within the Netherlands we work together with the Dutch Children Oncology Group (DCOG) –and the Rotterdam Ophthalmic Institute (ROI). Our working relation with the DCOG covers many  aspects ranging from statistical analysis concerning retrospective and prospective studies,  statistical design for new studies, seminars and lectures for children oncologists and advanced data management.
  • We have a strong participation in international studies  in the field of hematopoietic stem cell transplantation through our collaborations with the European Society for Blood and Marrow Transplantation (EBMT), and DKMS, the German Bone Marrow Donor Center.

Selected publications

  1. Schetelig J*, de Wreede LC*, van Gelder M et al. (2016) Risk Factors for Treatment Failure after Allogeneic Transplantation of patients with CLL: A Report from the European Society for Blood and Marrow Transplantation (EBMT) . Accepted, Bone Marrow Transplant
  2. van Gelder M*, de Wreede LC*, Bornhäuser M et al. (2016) Long-term Survival of Patients with CLL after Allogeneic Transplantation: A report from the European Society for Blood and Marrow Transplantation (EBMT).   Accepted, Bone Marrow Transplant
  3. Willeumier JJ*, Rüten-Budde AJ*, Jeys LM, Laitinen M,Rob Pollock R, Will Aston W, Dijkstra PDS, Ferguson PC, Griffin AM, Wunder JS, van de Sande MA, Fiocco M. Individualised risk assessment for local recurrence and distant metastases in a retrospective cohort of 687 patients with high -grade soft tissue sarcomas of the extremities: a multi-state model.  Accepted, BMJ
  4. Eefting M*, de Wreede LC*, Halkes CJ, von dem Borne PA, Kersting S, Marijt EW, Veelken H, Putter H, Schetelig J, Falkenburg JH (2016). Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.Haematologica 101: 506 – 514
  5. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, Egeler RM, Hoogerbrugge P, Kaspers G, Van der Schoot E, De Haas V. (2016) Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group. J Clin Oncol 34(22):2591-601
  6. Fontein DB, Klinten Grand M, Nortier JW, Seynaeve C, Meershoek-Klein Kranenbarg E, Dirix LY, van de Velde CJ, Putter H (2015). Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial. Ann Oncol 26: 1254 – 1262
  7. Wiltink LM, Nout RA, Fiocco M, Kranenbarg EM, Jürgenliemk-Schulz IM, Jobsen JJ, Nagtegaal ID, Rutten HJ, van de Velde CJ, Creutzberg CL, Marijnen CA (2015). No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials.J Clin Oncol, 33(15), 1640-1646
  8. Vriezinga SL, Auricchio R, Bravi E, Castillejo G, Chmielewska A, Crespo Escobar P, Kolaček S, Koletzko S, Korponay-Szabo IR, Mummert E, Polanco I, Putter H, Ribes-Koninckx C, Shamir R, Szajewska H, Werkstetter K, Greco L, Gyimesi J, Hartman C, Hogen Esch C, Hopman E, Ivarsson A, Koltai T, Koning F, Martinez-Ojinaga E, te Marvelde C, Pavic A, Romanos J, Stoopman E, Villanacci V, Wijmenga C, Troncone R, Mearin ML (2014). Randomized feeding intervention in infants at high risk for celiac disease. New England Journal of Medicine 371 : 1304—1315.
  9. Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M, de Witte TM, Kröger N, Ruutu T (2014). Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia 28: 2235—2240.
  10. Henneman D, van Bommel AC, Snijders A, Snijders HS, Tollenaar RA, Wouters MW, Fiocco M (2014). Ranking and Rankability of Hospital Postoperative Mortality Rates in Colorectal Cancer Surgery. Annals of Surgery 259: 844—849.
  11. de Wreede  LC,   Watson  M,  van Os M,  Milligan D,  van Gelder M,  Michallet M,  Dreger P,  Dearden CE,  Homewood J,  Dupuis J,  Leporrier M,  Karas M,  Corront B, Baerlocher GM,  Herr W,  Choquet S,  Niederwieser DW,  Sutton L,  Kröger N,  de Witte TM,  Schetelig J, On behalf Of The Chronic Malignancies Working Party Of The EBMT And The UK Medical Research Council (2013). Improved relapse-free survival after autologous stem cell transplantion does not translate into better Quality of Life in Chronic Lymphocytic Leukemia: Lessons from the randomized European Society for Blood and Marrow Transplantation-Intergroup study. American Journal of Hematology 89 : 174—180.
  12. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE (2011). Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377 : 321—331.
  13. Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL; PORTEC Study Group (2011). Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375: 816—823.